Endocrine system recommendations
On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net
| Title | Documents | Decision | Date | |
|---|---|---|---|---|
|
Updated 19/05/2023 |
FreeStyle Libre 2 and Dexcom One | NTAG CGM position statement - November 2022_FINAL - amended 21.2.23 | Recommended for use as per NICE guidance | 15/11/2022 |
| Insulin Glargine (Toujeo®) | Recommendation | Recommended as an option | 24/11/2015 | |
| Insulin Glargine Biosimilar(Abasaglar®) | Recommendation | Recommended first line | 24/11/2015 | |
|
Updated 07/06/2022 |
i-Port Advance® for use in children and adults with diabetes | Recommendation | Recommended as an option | 07/06/2022 |
| OmniPod® CSII system for diabetes | Recommendation | Recommended as an option | 02/06/2015 | |
| Semaglutide (oral) for type 2 diabetes | Recommendation | Recommended as an option for intensification of treatment, if use of GLP1RA is clinically appropriate, and if an oral option is preferred. | 01/09/2020 | |
| Teriparatide Biosimilar | Recommendation | Recommend for the treatment of osteoporosis in postmenopausal women as per NICE TA161 | 08/12/2020 | |
| Teriparatide for atypical bisphosphonate induced fractures | Recommendation | Not recommended | 23/02/2021 | |
|
Updated 19/05/2023 |
North East Guideline For Use Of Sodium Glucose Co transporter 2 Inhibitors (SGLT2i) | NENC regional SGLT2 top tips v1.2 - NTAG approved March 2023 | Approved by NTAG | 21/03/2023 |